Literature DB >> 16254399

Diffusion-weighted imaging with calculated apparent diffusion coefficient of enhancing extra-axial masses.

U Dorenbeck1, I Q Grunwald, J Schlaier, S Feuerbach.   

Abstract

BACKGROUND AND
PURPOSE: Sometimes intracranial contrast-enhancing tumors like meningiomas, metastases, lymphomas, and schwannomas can mimic each other. It was the aim of the present study to investigate if intracranial contrast-enhancing lesions can be reliably differentiated with the help of diffusion-weighted imaging with calculated apparent diffusion coefficients (ADCs).
METHODS: 29 patients (ages ranging from 22 to 82 years, mean age of 58.6 years) were included. Nine meningiomas, 7 metastases, 6 lymphomas, and 7 schwannomas were investigated. The ADC value in the lesions and in the perifocal edema was analyzed.
RESULTS: For the lymphomas, the authors measured the lowest ADC values in the contrast-enhancing part (0.59 +/- 0.09 . 10(-3) mm2/sec). The meningiomas showed a mean ADC value of 0.98 +/- 0.18 . 10(-3) mm2/sec. The schwannomas and metastases showed higher ADC values of 1.33 +/- 0.28 . 10(-3) mm2/sec and 1.05 +/- 0.20 . 10(-3) mm2/sec. The authors saw a statistically significant difference between lymphomas, meningiomas, and metastases concerning the ADC values in the contrast-enhancing part.
CONCLUSIONS: In spite of a small sample size and partly a wide range of values, the authors found statistically significant differences between meningiomas, metastases, and lymphomas concerning ADC values. Nevertheless, a differentiation of these lesions only with the help of ADC values seems questionable.

Entities:  

Mesh:

Year:  2005        PMID: 16254399     DOI: 10.1177/1051228405279991

Source DB:  PubMed          Journal:  J Neuroimaging        ISSN: 1051-2284            Impact factor:   2.486


  7 in total

1.  Intracranial dural chondroma in a child-conventional and advanced neuroimaging characteristics and differential diagnosis.

Authors:  Shai Shrot; Alan R Cohen; Fausto J Rodriguez; Frank Berkowitz; Bruno P Soares; Thierry Agm Huisman
Journal:  Neuroradiol J       Date:  2017-06-20

Review 2.  Use of T2 signal intensity of cerebellar neoplasms in pediatric patients to guide preoperative staging of the neuraxis.

Authors:  Jonathan A Forbes; Lola B Chambless; Jason G Smith; Curtis A Wushensky; Richard L Lebow; JoAnn Alvarez; Matthew M Pearson
Journal:  J Neurosurg Pediatr       Date:  2011-02       Impact factor: 2.375

Review 3.  Diffusion imaging of brain tumors.

Authors:  Stephan E Maier; Yanping Sun; Robert V Mulkern
Journal:  NMR Biomed       Date:  2010-08       Impact factor: 4.044

Review 4.  Schwannoma in and around the porta hepatis: radiological features in eight cases and literature review.

Authors:  Moto Nakaya; Ryo Kurokawa; Takeyuki Watadani; Hiroyuki Morisaka; Maika Higuchi; Yusuke Toda; Hideki Kunichika; Masashi Kusakabe; Yoshitaka Okada; Yoshimitsu Ohgiya; Masahiro Okada; Hiroshi Anai; Osamu Abe; Manabu Minami
Journal:  Abdom Radiol (NY)       Date:  2022-04-30

5.  Associations among q-space MRI, diffusion-weighted MRI and histopathological parameters in meningiomas.

Authors:  Zareen Fatima; Utaroh Motosugi; Ahmed Bilal Waqar; Masaaki Hori; Keiichi Ishigame; Naoki Oishi; Toshiyuki Onodera; Kazuo Yagi; Ryohei Katoh; Tsutomu Araki
Journal:  Eur Radiol       Date:  2013-03-22       Impact factor: 5.315

6.  Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival.

Authors:  Christina Chen; Raymond Huang; Ainsley MacLean; Alona Muzikansky; Srinivasan Mukundan; Patrick Y Wen; Andrew D Norden
Journal:  J Neurooncol       Date:  2013-08-22       Impact factor: 4.130

Review 7.  Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response.

Authors:  Raymond Y Huang; Martha R Neagu; David A Reardon; Patrick Y Wen
Journal:  Front Neurol       Date:  2015-02-23       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.